Skip to main content

Table 1 Baseline characteristics of the 94 patients

From: Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Characteristic

Median or percentage

IQR

Gender (masculine)

77.7%

 

Age (years)

52

13

Risk factor for HIV

  

Heterosexual contacts

54.3%

 

Homosexual contacts

23.4%

 

Intravenous drug use

20.2%

 

Other

2.1%

 

Number of ARV drug lines

3

4

Time on cART (years)

10

12

Time on current cART (months)

37.5

61

Time below detection limit for HIV (months)

77.5

61

Drugs in baseline ARV regimen (patients treated with drug)

  

TDF

52.1%

 

ABC

36.2%

 

AZT

3.2%

 

EFV

28.7%

 

NVP

13.8%

 

RPV

10.6%

 

ETR

4.3%

 

ATV/r

13.8%

 

DRV/r

12.8%

 

APV/r

1.1%

 

LPV/r

1.1%

 

RAL

9.6%

 

DTG

5.3%

 

EVG

2.1%

 

CD4 (cells/mcL)

673

403

Reasons for drug switch

  

Concomitant disease

30.9%

 

Abnormal laboratory test

28.7%

 

Adverse Events

19.1%

 

Drug/drug interaction

13.8%

 

Concomitant diseases + abnormal laboratory test

4.3%

 

Adverse events + drug/drug interaction

2.1%

 

Abnormal laboratory test + drug/drug interaction

1.1%

Â